Abstract
Since its introduction into clinical practice some 20 years ago, cisplatin has made a major impact on the response rates of several human malignancies, notably testicular and ovarian cancers. Nonetheless, this drug does have limitations: its severe side-effects, its poor activity against some common tumours (e.g. breast and non small cell lung cancers, Loehrer and Einhorn, 1984) and its inability to confer lasting remissions in responding tumour types (especially ovary) due to the emergence of drug resistance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Andrews P.A. and Howell S.B., 1990, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 36
Burchenal J.H., Irani G., Kern K., Lokys L and Turkevich J., 1980, 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Rec. Res. Cancer Res. 74: 146
Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., Jones A.C., NcElwain T.J., Raju S., Wiltshaw E., Smith I.E., Baker J.M., Peckham M.J. and Harrap K.R., 1982, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother. Pharmacol. 9: 140
de Graeff A., Slebos R.J.C. and Rodenhuis S., 1988, Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother. Pharmacol. 22: 325
Eisenhauer E., Swerton K., Sturgeon J., Fine S., O’Reilly S. and Canetta R., 1990, Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature, in: “Carboplatin: Current Perspectives and Future Directions”, P. Bunn, R. Canetta, R. Ozols and M. Rozencweig, eds., W.B. Saunders Company, Philadelphia, p. 133.
Evans B.D., Raju K.S., Calvert A.H., Harland S.J. and Wiltshaw E., 1983, JM8 (cis-diammine-1,1-cyclobutane dicarboxylate platinum II), a new platinum analogue active in the treatment of advanced ovarian carcinoma. Cancer Treat. Rep. 67: 997
Gore M., Fryatt I., Wiltshaw E., Dawson T., Robinson B. and Calvert A., 1989, Cisplatin/carboplatin cross-resistance in ovarian cancer. Br. J. Cancer 60: 767
Harrap K.R., 1985, Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12 (Suppl. A): 21.
Harrap K.R., Jones M., Goddard P.M., Orr R.M. and Siddik Z.H., 1988, Drug resistance as a focus for new drug design, in: “Mechanisms of Drug Resistance in Neoplastic Cells — Bristol-Myers Cancer Symposia, Volume 9”, P.V. Woolley and K.D. Tew, eds., Academic Press, New York, p. 307.
Harrap K.R., Jones M., Siracky J., Pollard LA. and Kelland L.R., 1990, The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Annals of Oncology 1: 65
Harrap K.R., Kelland L.R., Jones M., Goddard P.M., Orr R.M., Morgan S.E., Murrer B.A., Abrams M.J. and Giandomenico C.M., 1991, Platinum coordination complexes which circumvent cisplatin resistance. Adv. Enzyme Regln. 31: in press.
Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P. and Harrap K.R., 1989, Biological properties often human ovarian carcinoma cell lines: calibration in vitro against 4 platinum complexes. Br. J. Cancer 59: 527
Loehrer P. and Einhorn L, 1984, Cisplatin. Ann. Int. Med. 100: 704
Morrison, S.D., 1983, In vivo estimation of size of experimental tumours. J. Natl. Cancer Inst. 71: 407
Orr R.M., O’Neill C.F., Murrer B.A., Nicolson M.C. and Harrap K.R., 1989, Evaluation of novel platinum II and platinum IV ammine/amine complexes using L1210 sublines resistance to cisplatin or tetraplatin. Proc. Am. Assoc. Cancer Res. 30: 509
Siddik Z.H., Boxall F.E. and Harrap K.R., 1987, Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilised in hyamine hydroxide. Analyt. Biochem. 163: 21
Skehan P., Storreng R., Scudiero N., Monks A., McMahon J., Vistica D., Warren J., Bokesh H., Kinney S. and Boyd M., 1989, Evaluation of colorimetric and biomass stains for assaying in vitro drug effects upon human tumour cells. Proc. Am. Assoc. Cancer Res. 30: 612
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Harrap, K.R. et al. (1991). Ammine/Amine Platinum IV Dicarboxylates: A Novel Class of Complexes Which Circumvent Intrinsic Cisplatin Resistance. In: Howell, S.B. (eds) Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0738-7_36
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0738-7_36
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0740-0
Online ISBN: 978-1-4899-0738-7
eBook Packages: Springer Book Archive